EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review

Yang-Kai Fu, Yi-Nan Li, De-Yi Liu, Zhen-Xin Zeng, Jia-Yi Wu, Jun-Yi Wu, Jin-Xiu Wang, Han Li, Xiang-Ye Ou, Mao-Lin Yan

Oncology Research and Treatment · 2024

DOI: 10.1159/000540662 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Research and Treatment, 2024. Verfasst von Yang-Kai Fu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shengli Clinical Medical College of Fujian Medical University, Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, Ch…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms, Phenylurea Compounds. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patients with hepatocellular carcinoma (HCC) and inferior vena cava tumor thrombus (IVCTT) have poor prognosis. Combination therapy involving the blockade of programmed cell death protein 1 (PD-1) and tyrosine kinase inhibitors is an efficient treatment strategy for advanced HCC. However, surgical treatment after a combination of systemic therapy and transarterial chemoembolization (TACE) for HCC with IVCTT has not been widely reported, and the efficacy and safety of this treatment have not been studied.

Methods

In the 21 cases reported herein, the patients were treated with TACE, lenvatinib, and PD-1 blockade. The treatment responses, progression-free survival (PFS), overall survival (OS), disease control rate, and toxicities were evaluated, and the related literature was reviewed.

Results

The overall response and disease control rates were 66.7% and 85.7%, respectively. The median PFS time was 16.0 months, with a 1-year PFS rate of 55.60%. The median OS was not reached, with a 1-year OS rate of 66.70%. Four patients underwent hepatectomy without serious complications and survived for 29.1, 24.7, 14.2, and 13.8 months. Three patients survived tumor-free, and 1 patient experienced intrahepatic recurrence. Pathological complete response and major pathological responses were observed in 1 and 3 patients, respectively. Treatment-related adverse events of any grade occurred in 8/9 patients (88.9%), and grade 3 treatment-related adverse events occurred in 1 patient.

Conclusion

The combination of TACE, lenvatinib, and PD-1 is effective for HCC with IVCTT and has acceptable adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsPhenylurea CompoundsQuinolinesVena Cava, InferiorHumansCombined Modality TherapyImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorTreatment Outcome

Stichwörter der Autor:innen

Combination therapyHepatectomyHepatocellular carcinomaInferior vena cava tumor thrombus

Substanzen

Immune Checkpoint InhibitorslenvatinibPDCD1 protein, humanPhenylurea CompoundsProgrammed Cell Death 1 ReceptorQuinolines

Autor:innen und Institutionen

  • Shengli Clinical Medical College of Fujian Medical University, Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, China.
  • Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, China.

Zitieren

APA

Fu, Y. K., Li, Y. N., Liu, D. Y., Zeng, Z. X., Wu, J. Y., Wu, J. Y., Wang, J. X., Li, H., Ou, X. Y., & Yan, M. L. (2024). Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review. Oncology Research and Treatment. https://doi.org/10.1159/000540662

Vancouver

Fu YK, Li YN, Liu DY, Zeng ZX, Wu JY, Wu JY, et al. Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review. Oncology Research and Treatment. 2024. doi:10.1159/000540662

BibTeX
@article{Fu2024,
  author = {Fu, Yang-Kai and Li, Yi-Nan and Liu, De-Yi and Zeng, Zhen-Xin and Wu, Jia-Yi and Wu, Jun-Yi and Wang, Jin-Xiu and Li, Han and Ou, Xiang-Ye and Yan, Mao-Lin},
  title = {Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review},
  journal = {Oncology Research and Treatment},
  year = {2024},
  doi = {10.1159/000540662}
}
Kostenlos starten →